Subtopic Deep Dive

ACMG Variant Interpretation Guidelines
Research Guide

What is ACMG Variant Interpretation Guidelines?

ACMG Variant Interpretation Guidelines provide standardized criteria for classifying germline sequence variants as pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, or benign in clinical genomics.

Joint ACMG/AMP recommendations by Richards et al. (2015) established 28 evidence criteria across population, computational, segregation, and functional data, cited 30,258 times. Li et al. (2016) adapted these for cancer somatic variants, cited 1,882 times. Brnich et al. (2019) refined PS3/BS3 functional evidence rules, cited 562 times.

15
Curated Papers
3
Key Challenges

Why It Matters

Standardized classification by Richards et al. (2015) enables reproducible reporting of germline variants in cancer predisposition genes like TP53 and BRCA1/2, guiding precision oncology decisions. Zhang et al. (2015) applied guidelines to pediatric cancer cohorts, identifying 8.5% germline mutations missed by family history. Li et al. (2016) cancer-specific rules reduce VUS rates in tumor sequencing, improving therapeutic targeting in metastatic solids as in Priestley et al. (2019). CIViC database by Griffith et al. (2017) crowdsources interpretations for 648+ citations.

Key Research Challenges

Functional Evidence Standardization

PS3/BS3 criteria require validated assays, but variability across labs complicates strong evidence assignment. Brnich et al. (2019) recommend standardized functional tests for ACMG/AMP application. Cancer-specific assays lag germline standards per Li et al. (2016).

VUS Resolution in Cancer Genes

High VUS rates in predisposition genes hinder clinical action. Zhang et al. (2015) found family history poor predictor in pediatric cases. Population databases like HGMD (Stenson et al., 2017) aid benign calls but germline-cancer overlap confounds.

Somatic vs Germline Distinction

Cancer guidelines by Li et al. (2016) adapt ACMG for tumors, but incidental germline findings need Richards et al. (2015) rules. Green et al. (2013) set reporting thresholds for 56 genes. Whole-genome data like Priestley et al. (2019) amplify classification challenges.

Essential Papers

2.

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

Robert C. Green, Jonathan S. Berg, Wayne W. Grody et al. · 2013 · Genetics in Medicine · 2.5K citations

3.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Marilyn M. Li, Michael Datto, Eric J. Duncavage et al. · 2016 · Journal of Molecular Diagnostics · 1.9K citations

5.

Germline Mutations in Predisposition Genes in Pediatric Cancer

Jinghui Zhang, Michael F. Walsh, Gang Wu et al. · 2015 · New England Journal of Medicine · 1.3K citations

Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an underlying predisposition synd...

6.

Pan-cancer whole-genome analyses of metastatic solid tumours

Peter Priestley, Jonathan Baber, Martijn P. Lolkema et al. · 2019 · Nature · 1.1K citations

Abstract Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A better understanding of the characteristics of late-stage cancer is required to help adapt per...

7.

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

Malachi Griffith, Nicholas C. Spies, Kilannin Krysiak et al. · 2017 · Nature Genetics · 648 citations

Reading Guide

Foundational Papers

Start with Richards et al. (2015) for 28 core criteria; Green et al. (2013) for incidental findings reporting; Brownstein et al. (2014) CLARITY Challenge for interpretation standards validation.

Recent Advances

Li et al. (2016) cancer guidelines; Brnich et al. (2019) PS3/BS3 refinements; Griffith et al. (2017) CIViC for crowdsourced cancer interpretations.

Core Methods

Population frequency (gnomAD/1000G via BA1/BS1); computational predictors (REVEL, SIFT via PM1/PP3); functional assays (PS3/BS3); segregation (PP1/BS4); databases (HGMD, ClinVar).

How PapersFlow Helps You Research ACMG Variant Interpretation Guidelines

Discover & Search

Research Agent uses searchPapers on 'ACMG cancer germline variants' to retrieve Richards et al. (2015) (30k citations); citationGraph maps adaptations like Li et al. (2016); findSimilarPapers expands to Brnich et al. (2019); exaSearch drills into PS3/BS3 functional assays.

Analyze & Verify

Analysis Agent runs readPaperContent on Richards et al. (2015) to extract 28 criteria tables; verifyResponse with CoVe cross-checks classifications against Li et al. (2016); runPythonAnalysis computes VUS rates from Zhang et al. (2015) cohort data using pandas; GRADE scores evidence strength for PS3/BS3 per Brnich et al. (2019).

Synthesize & Write

Synthesis Agent detects gaps in functional assays for cancer genes; flags contradictions between germline (Richards 2015) and somatic (Li 2016) rules; Writing Agent uses latexEditText for variant tables, latexSyncCitations for 10+ papers, latexCompile for guideline flowcharts, exportMermaid for PS3/BS3 decision trees.

Use Cases

"Calculate VUS reduction using ACMG in pediatric cancer cohorts"

Research Agent → searchPapers(Zhang 2015) → Analysis Agent → runPythonAnalysis(pandas on 8.5% mutation rates, matplotlib VUS plots) → researcher gets CSV of reclassified variants with stats.

"Draft LaTeX report comparing ACMG germline vs cancer guidelines"

Synthesis Agent → gap detection(Richards 2015 vs Li 2016) → Writing Agent → latexEditText(merge criteria), latexSyncCitations(10 papers), latexCompile → researcher gets PDF with cited tables and Mermaid flowchart.

"Find code for ACMG variant classification in cancer genomics repos"

Research Agent → paperExtractUrls(Griffith CIViC 2017) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python classifiers for PS3/BS3 with usage examples.

Automated Workflows

Deep Research workflow scans 50+ ACMG papers via searchPapers → citationGraph → structured report on cancer adaptations (Richards to Li). DeepScan's 7-steps verify PS3/BS3 assays: readPaperContent(Brnich 2019) → CoVe → runPythonAnalysis(functional data stats). Theorizer generates hypotheses for VUS resolution from Zhang (2015) + HGMD (Stenson 2017) patterns.

Frequently Asked Questions

What is the core ACMG variant classification framework?

Richards et al. (2015) define 5 categories (pathogenic, likely pathogenic, VUS, likely benign, benign) using 28 criteria weighted pathogenic (PVS1-3, PM1-6), supporting (PP1-5), benign (BA1-4, BS1-4).

How do cancer-specific ACMG guidelines differ?

Li et al. (2016) adapt for somatic variants, emphasizing allele frequency in tumors, pathology, and treatment response over germline segregation.

What are key papers on ACMG in cancer?

Richards et al. (2015, 30k cites) foundational; Li et al. (2016, 1.8k cites) cancer; Brnich et al. (2019, 562 cites) PS3/BS3; Zhang et al. (2015) pediatric application.

What open problems remain in ACMG application?

Standardizing functional assays (Brnich 2019), resolving VUS in diverse populations, integrating somatic-germline (Li 2016, Green 2013), and scaling to whole-genome data (Priestley 2019).

Research Cancer Genomics and Diagnostics with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching ACMG Variant Interpretation Guidelines with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.